Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CytRx Corp. (CYTR) And Kitov Pharamceuticals Holdings Ltd. (KTOV) Activist Update

|Includes: CytRx Corporation (CYTR), KTOV

When a person or group of persons acquires beneficial ownership of more than 5% of a company’s equity securities, they are required to file a Schedule 13D or 13G with the SEC. If these groups intend to influence management into changing the business strategy, they are considered "activist" investors. There is considerable academic research that suggest activist investors contribute to excess returns in equities in the subsequent twelve months after the event.

Sabby Management, LLC has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,100,000 shares of CytRx Corp. (NASDAQ:CYTR). This represents 9.22 percent ownership of the company. Previously, Sabby Management, LLC had reported owning 1,148,883 shares, indicating an increase of 169.83 percent. CytRx Corp. has declared a standard industrial code (sic) of 2836 which is the "Biological Products, Except Diagnostic Substances (Biotech)" industry.

Rosalind Advisors, Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 541,600 shares of Kitov Pharamceuticals Holdings Ltd.(NASDAQ:KTOV). This represents 4.7 percent ownership of the company. Previously, Rosalind Advisors, Inc. had reported owning 1,105,600 shares, indicating a decrease of -51.01 percent.

Investors that acquire 10% or more of a company's shares, or that gain a board seat, are considered insiders by the SEC and are subject to stricter insider trading filing requirements.

New Activist Investor Filings

Investors that acquire more than 5% of the shares of a company and intend to influence management are considered activist investors and must file a 13D.

Gridsum Holding Inc. (NASDAQ:GSUM) - Futurex Innovation Spc has filed a new SC 13D, reporting a 20.00% ownership stake in Gridsum Holding.

Amended Activist Investor Filings

Virtu Financial, Inc. (NASDAQ:VIRT) - Temasek Holdings (Private) Ltd has filed an amended Schedule 13D/A, reporting a 16.20% ownership stake in Virtu Financial. This is a decrease of 28.00% from their previous filing.

RAIT Financial Trust (NYSE:RAS) - Frischer Charles has filed an amended Schedule 13D/A, reporting a 8.00% ownership stake in RAIT Financial Trust. This is an increase of 25.79% from their previous filing.

Geospace Technologies Corp (NASDAQ:GEOS) - Lemelson Capital Management LLC has filed an amended Schedule 13D/A, reporting a 9.30% ownership stake in Geospace Technologies. This is an increase of 10.71% from their previous filing.

Alaska Communications Systems Group, Inc. (NASDAQ:ALSK) - Singer Karen has filed an amended Schedule 13D/A, reporting a 5.12% ownership stake in Alaska Communications Systems Group. This is an increase of 1.79% from their previous filing.

New Passive Investor Filings

Investors that acquire more than 5% of the shares of a company but have no intention of influencing management are considered passive investors and must file a 13G.

Stellar Biotechnologies Inc. (NASDAQ:SBOT) - Sabby Management, LLC has filed a new SC 13G, reporting a 9.99% ownership stake in Stellar Biotechnologies.

CytRx Corp. (NASDAQ:CYTR) - Sabby Management, LLC has filed a new SC 13G, reporting a 9.22% ownership stake in CytRx. This is an increase of 121.63% from their previous filing.

Amended Passive Investor Filings

Kitov Pharamceuticals Holdings Ltd. (NASDAQ:KTOV) - Rosalind Advisors, Inc. has filed an amended Schedule 13D/A, reporting a 4.70% ownership stake in Kitov Pharamceuticals Holdings. This is a decrease of 51.55% from their previous filing.

MoSys, Inc. (NASDAQ:MOSY) - Hirschman Orin has filed an amended Schedule 13D/A, reporting a 0.00% ownership stake in MoSys. This is a decrease of 100.00% from their previous filing.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) - Novartis Bioventures Ltd has filed an amended Schedule 13D/A, reporting a 9.80% ownership stake in Aeglea BioTherapeutics. This is a decrease of 43.02% from their previous filing.

Fintel provides free investor tools for data driven investors. Get full coverage of Renaissance Technologies LLC or FINL: The Finish Line Analysis and Research Report. Check out Fintel Dashboard.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.